Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Inclusion Criteria:

1. Subjects able to sign the informed consent and ≥18 y-old.

2. Histologically or cytologically confirmed diagnosis of HNSCC.

3. Confirmed R/M HNSCC (i.e. oral cavity, oropharynx, larynx, hypopharynx) not suitablefor curative loco-regional therapy.

4. PD-L1 CPS≥1≤19 (assessment allowed either on primary and/or recurrent/metastaticsite of disease).

5. Measurable disease according to RECIST Criteria 1.1.6. Subjects should not have hadprior systemic therapy administered in the R/M HNSCC setting.

7.Systemic therapy that was completed more than 6 months prior to signing consent, if given as a part of multimodal curative treatment for locally advanced disease, is allowed.

8.ECOG Performance Status (PS) 0-1. 9.Adequate bone marrow function: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 9 g/dL.

10.Adequate liver function: total bilirubin level < 1.5 X Upper Limit of Normal (ULN) (except for known medical reason not interfering with liver function, such as Gilbert syndrome), AP, GGT <3 x ULN and AST and ALT levels ≤ 2.5 × ULN.

11.Adequate renal function: calculated or analyzed creatinine clearance ≥ 30 mL/min.

12.Archival or fresh tissue of primary disease (i.e. T and/or N and/or M) OR recurrent/metastatic disease available at baseline (before starting TPE) (available as Formalin-Fixed Paraffin-Embedded - FFPE - or as unstained 10-20 slices).

13.Participants have to provide peripheral blood samples (at least 8-10 mL stored in EDTA) according the timing described in the translational part of the current protocol.

14.Palliative radiotherapy and/or surgery within 4 weeks before the study entry are allowed.

15.Symptomatic peripheral neuropathy NCI-CTC v5.0 grade ≥ 2 and / or ototoxicity grade ≥ 2, (except for cases in which ototoxicity is due to trauma or tumor-related mechanical impairment) or creatinine clearance < 60 mL/min are acceptable and they must be approached with carboplatin (instead of cisplatin) since the trial start.

Exclusion criteria:

1. Nasopharyngeal, salivary gland, nasal sinus, and non-melanoma skin cancers are notallowed.

2. Life expectancy lower than 3 months according to the judgement of trial investigatoris not allowed.

3. Previous chemotherapy, or biological therapy (i.e. Cetuximab), or immunotherapyadministered for R/M setting of HNSCC is not allowed.

4. Diagnosis of immunodeficiency or subjects receiving systemic steroid therapy (> 10mg/day of prednisone or equivalent) or any other form of immunosuppressive therapywithin 30 days prior to start of study treatment which cannot be interrupted.

5. Known allergic/hypersensitivity reaction to investigational products or anycomponent in their formulations.

6. Active autoimmune disease that has required systemic treatment in past 2 years (i.e.with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

7. Active autoimmune disease that might deteriorate when receiving animmuno-stimulatory agent. Patients with type I diabetes, vitiligo, psoriasis, orhypo- or hyperthyroid diseases not requiring immunosuppressive treatment areeligible.

8. Any diagnosed and/or treated additional malignancy within 5 years before the studyentry with the exception of: curatively treated basal cell carcinoma of the skin,curatively treated squamous cell carcinoma of the skin, curatively treated prostatecancer, curatively resected in situ cervical cancer, and curatively resected in situbreast cancer.

9. Subjects with a history or current evidence of any condition, therapy, or laboratoryabnormality that might confound the results of the trial, interfere with thesubjects' participation for the full duration of the trial, or is not in the bestinterest of the subject to participate, according to the opinion of the treatinginvestigator.

10. Significant neurologic or known psychiatric or substance abuse disorders that wouldinterfere with cooperation and the requirements of the trial.

11. Clinically significant (i.e., active) cardiovascular disease: cerebral vascularaccident/stroke (≤6 months prior to enrollment), myocardial infarction (≤6 monthsprior to enrollment), unstable angina, congestive heart failure (≥ New York HeartAssociation Classification Class II), or serious cardiac arrhythmia requiringmedication.

12. Prior organ transplantation including allogenic stem-cell transplantation.

13. Active uncontrolled infection requiring systemic therapy (i.e. I.V. antibiotics).

14. Known history of testing positive for HIV or known acquired immunodeficiencysyndrome.

15. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positiveHBV surface antigen or HCV RNA if anti-HCV antibody screening tests positive).

16. Live vaccination within 30 days of planned start of study treatment (inactivatedvaccines are allowed).

17. Pregnancy (absence of pregnancy must be confirmed by negative serum or urinepregnancy test - ß-HCG - for women of childbearing potential) and/or breast-feedingare not allowed. Subjects of childbearing potential willing to use effectivecontraceptive method [Pearl Index < 1; e.g. oral contraceptive (pill), hormonespiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), sterilization, sexual abstinence] for the entire studyduration and 30 days post-dosing.